Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409052 · ClinicalTrials.gov registry record
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
A clinical trial of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06409052: Recruiting study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06409052 is a study of Endometrial Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06409052, a study of Endometrial Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
Primary Outcome
To build a patient tool for educating and empowering women to make informed decisions about endometrial cancer prevention strategies.
Conditions Studied
Interventions
- BEHAVIORAL Qualitative interviews
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2026-08-03 |
What NCT06409052 shows while recruiting
NCT06409052 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Qualitative interviews is the first listed.
NCT06409052 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06409052 about?
NCT06409052 is a clinical study titled "Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women". To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
What is the current status of trial NCT06409052?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2024-06-25. Estimated completion is 2026-08-03.
What conditions does trial NCT06409052 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06409052?
The interventions under investigation include: Qualitative interviews (BEHAVIORAL).
Who is sponsoring clinical trial NCT06409052?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409052 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06409052's enrollment target sits among peer trials
45 131st of 181 higher than 50 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI